Why Ozempic might help tackle aging

Glucagon-like peptide-1 receptor agonists such as Ozempic, originally developed for diabetes management and later approved for weight loss, are being studied for their potential to address age-related diseases, The Wall Street Journal reported March 10. 

Read the full post on Becker's Hospital Review | Healthcare News & Analysis